Načítá se...
Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
Biosimilars are being marketed in India since 2000. Like biologics, biosimilars have a large size, complex structure, and complicated manufacturing process, and they are produced in a living organism. It requires specialized delivery devices for administration and needs tighter temperature control t...
Uloženo v:
| Vydáno v: | J Postgrad Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer - Medknow
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6813686/ https://ncbi.nlm.nih.gov/pubmed/31571620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/jpgm.JPGM_109_19 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|